COMP <GO>
SNDX vs AMPH // 10Y YIELD & FRED MACRO BETA
Syndax Pharmaceuticals Inc. (NASDAQ) VS. Amphastar Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: SNDX 2
— AMPH 6
■ METRIC PARITY
LAST: $13.10 (-4.03%) • MKT CAP: $1.22B
macro-sensitivity
—
LAST: $27.03 (-2.49%) • MKT CAP: $1.18B
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SNDX VS. AMPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SNDX | AMPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 49.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 9.00% | -44.00 | AMPH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 9.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 10.58% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 19.50% | -79.50 | AMPH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 13.60% | -73.60 | AMPH | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | -1.70% | +181.70 | SNDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 2.47 | -2.27 | AMPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | AMPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.8 | 63.6 | -25.80 | AMPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 10.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.22B | $1.18B | $39.8M | SNDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SNDX REV | AMPH REV | SNDX GROSS % | AMPH GROSS % | SNDX FCF | AMPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $172.4M | $719.9M | — | 49.5% | -$323.2M | $121.2M |
| FY 2024 | $23.7M | $732.0M | — | 51.1% | -$274.9M | $172.3M |
| FY 2023 | $643.9M | $644.4M | — | — | -$160.6M | $183.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SNDX // BETA —
AMPH // BETA —